Skip to main content

Anti-Rheumatic Rx

hidradenitis.jpg

Inflammatory Arthritis and Hidradenitis Suppurativa

Dec 09, 2022

Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by persistent or 

Read Article
RheumNow Podcast square

Biosimilar Bonanza in 2023 (12.9.2022)

Dec 09, 2022

Dr. Jack Cush reviews more than a dozen news and journal articles from this past week on RheumNow.com. 

Read Article
cancer search news magnify

Xeljanz Cancer Risks Detailed

MedPage Today
Dec 07, 2022

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.



Tofacitinib at either 5 or 10 mg twice daily in the so-called ORAL

Read Article
PSA068.jpg

Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis

Dec 07, 2022

Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.



The BE COMPLETE study was a phase

Read Article
cardiac2.jpg (keep)

TARGET Trial - Cardiovascular Risk Reduction in Rheumatoid Arthritis

Dec 05, 2022

A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).

Read Article
cost.price_.biologic.injectable.jpg

Comparing Biosimilar Growth in the US, Germany, and Switzerland

Dec 05, 2022

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. This analysis of the uptake and price of biologic therapy in Germany, Switzerland and the United States suggest that anticompetitive practices in the US could allow

Read Article
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx
Steroid injections worsen knee arthritis Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease. https://t.co/pAeU3IzZfx https://t.co/rgJeHM5t62
Can I stop Methotrexate in RA? Dr. Pope and Dr. Meng discuss Abstract 0916 at #ACR22. https://t.co/0hK5kNHlrS https://t.co/AXJija7Yzo
pregnancy,embryo,fetal

Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth

Dec 02, 2022

Pregnant women with systemic lupus erythematosus (SLE) were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to national administrative data.



The cross-sectional study supports the role that the

Read Article
RheumNow Podcast square

Rheum Manpower Needs - More Programs! (12.2.2022)

Dec 02, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.




  1. NRMP Results for rheumatology 2022 : - Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied) - Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29

Read Article
COVID.virus_.corona.jpg (keep)

Rheum Drugs & IDSA Guidelines to Treat COVID-19

Dec 01, 2022

The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.

Read Article
infusion.biologic.jpg

RECITAL Trial: RTX vs. CTX in CTD-ILD

Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Just Can’t Get Enough of Hydroxychloroquine

Nov 30, 2022

When it comes to hydroxychloroquine dosing, issues on efficacy, toxicity and therapeutic thresholds may affect the optimal use of this important drug.

Following are three abstracts presented during the meeting that address these topics.

Read Article
Knee,injection

Steroid injections worsen knee arthritis

EurekAlert!
Nov 30, 2022

Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease. Results of both studies were presented today at the annual meeting of the Radiological Society of North America (

Read Article
230px-Sjogren_syndrome_%282%29.jpg

Low Dose IL-2 Therapy in Sjögren’s

Nov 29, 2022

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article
lupus SLE

Tyk2 Inhibition Effective in SLE

Nov 28, 2022

Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.



The results of this phase II trial were recently presented at ACR 2022. This  phase II multinational trial enrolled 363 adults with

Read Article
pregnancy,doctor,consult

Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies

Nov 25, 2022

Discussions regarding family planning, contraception, and pregnancy should be approached at each clinic visit to ensure providers understand patients’ personal goals. These conversations have the potential to decrease the risk of unplanned pregnancies. However, rheumatologists may need to manage

Read Article
heart2.ekg_.red_.jpg

RA: MACE Events with Opioids vs. NSAIDs

Addressing chronic pain often leads general practitioners and specialists to prescribe opioids. However, opioids (weak and strong) have not demonstrated efficacy in long-term pain management; their chronic use could even worsen pain in users. Opioids prescription is often perceived as being

Read Article
question-mark-1872634_640.jpg

Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines

In the wake of the 2016 AAOS Guidelines, rheumatologists dutifully reduced the dose HCQ take by patients with SLE to some number south of 5mg/kg per day. Though I believe the ophthalmologists correctly interpreted a 2014 paper in JAMA Ophthalmology that quoted a much-higher rate of HCQ

Read Article
RheumNow Podcast square

ACR 2022 Appraisal, Praise & Critique (11.18.2022)

Nov 18, 2022

It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle. 



I loved the city, but not the convention center (not easy to navigate). 



The meeting itself was very

Read Article
gout.MTP_.jpg

Methotrexate + pegloticase increases response rates in gout

In abstract 0001 presented at ACR22 Convergence, researchers presented 12-month data from a randomized double-blind placebo-controlled trial of pegloticase with or without MTX.

Read Article
Best of

ACR Best Abstracts - Day 3

Nov 14, 2022

The last day was jammed with important reports and research including the late breaking abstracts. 



 

Read Article
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
×